Latest filing published 02 Oct 2026 for Opus Genetics, Inc., €2.4M.
Filing timeline
BuySaleInsider track record
No signal scores available.
Foundation Fighting Blindness Retinal Degeneration Fund: trading record in brief
Foundation Fighting Blindness Retinal Degeneration Fund appears in our data through filings on Opus Genetics, Inc. shares, published by SEC (Form 4). The record holds 3 filings, for trades running from 5 May 2025 to 30 September 2026.
The open-market record consists of 2 sales worth €9.8M, with no purchase. In 2026 alone, the filings show no purchases and 1 sale.
The latest filing, published on 2 October 2026, reports an open-market sale of €2.4M in Opus Genetics, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Foundation Fighting Blindness Retinal Degeneration Fund
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 556,000 shares@ US$4.9568Common StockSEC:0002042266-26-000002:0
- 4,000,000 shares@ US$2.15100.0% of flowCommon StockSEC:0002042266-25-000003:0
- 6,927,419 sharesCommon StockSEC:0001578563-25-000238:0
3 of 3 declarations
